



NDA 22287-S34

SUPPLEMENT APPROVAL

Takeda Pharmaceuticals U.S.A., Inc.
Attention: Kinnari Shah
Sr. Manager, Global Regulatory Affairs Marketed Products
95 Hayden Avenue
Lexington, MA 02421

Dear Ms. Shah:

Please refer to your supplemental new drug application (sNDA) dated and received October 14, 2020, received and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for DEXILANT (dexlansoprazole) delayed-release capsules.

We also refer to our letter dated June 18, 2020, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for proton pump inhibitors (PPIs). This information pertains to the risk of subclinical acute or chronic interstitial nephritis associated with PPIs leading to chronic renal inflammation and reduced renal function reported in published literature.

This supplemental new drug application provides for revisions to the labeling for DEXILANT. The agreed upon changes to the language included in our June 18, 2020, letter are as follows (additions are noted by underline and deletion are noted by ~~strike through~~).

Other edits to reflect the changes and minor editorial revisions of formatting and commas are included in the attached label.

5.2 Acute Tubulointerstitial Nephritis

Acute (b) (4) ubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms (b) (4) from symptomatic (b) (4) hypersensitivity reactions to non-specific symptoms of decreased renal function (e.g., malaise, nausea, anorexia) (b) (4) (b) (4) In reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (e.g., fever, rash or arthralgia). (b) (4) (b) (4)

Discontinue DEXILANT and evaluate patients with suspected acute (b) (4)
(b) (4) TIN. - (b) (4)
(b) (4) [see Contraindications (4)].

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

We note that your November 12, 2020, submission includes final printed labeling (FPL) for your Prescribing Information and Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the wording in this FPL is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Andrew Kelleher, Regulatory Project Manager, at (240) 402-0075.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology (DG)
Office of Immunology and Inflammation (OI)
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JOYCE A KORVICK
11/27/2020 08:31:23 AM